Literature DB >> 11914992

Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.

J L Trouillet1, A Vuagnat, A Combes, N Kassis, J Chastre, C Gibert.   

Abstract

We sought to determine the epidemiological characteristics of patients in an intensive care unit (ICU) who developed ventilator-associated pneumonia (VAP) caused by piperacillin-resistant Pseudomonas aeruginosa (PRPA; n=34) or piperacillin-susceptible P. aeruginosa (PSPA; n=101). According to univariate analysis, the factors associated with the development of PRPA VAP were presence of an underlying fatal medical condition, immunocompromised status, longer previous hospital stay, less-severe illness at the time of ICU admission, duration of mechanical ventilation before onset of VAP, number of classes of antibiotic received, and previous exposure to imipenem or fluoroquinolone. Multivariate logistic regression analysis identified the following significant independent factors: presence of an underlying fatal medical condition (odds ratio [OR], 5.6), previous fluoroquinolone use (OR, 4.6), and initial disease severity (OR, 0.8). We concluded that the clinical characteristics of patients who develop PRPA VAP differ from those of patients who develop PSPA VAP. Restricted fluoroquinolone use is the sole independent risk factor for PRPA VAP that is open to medical intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914992     DOI: 10.1086/339488

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

1.  Pseudomonas aeruginosa bacteremia in children.

Authors:  Jana Koprnova; Jarmila Korcova; Maria Gogova; Vladimir Krcmery
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.

Authors:  Samer A Alyaseen; Kerryl E Piper; Mark S Rouse; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century.

Authors:  Jordi Rello; Bárbara Borgatta; Thiago Lisboa
Journal:  Intensive Care Med       Date:  2013-10-22       Impact factor: 17.440

4.  Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

Authors:  Y-A Que; H Lazar; M Wolff; B François; P-F Laterre; E Mercier; J Garbino; J-L Pagani; J-P Revelly; E Mus; A Perez; M Tamm; J-J Rouby; Q Lu; J Chastre; P Eggimann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 3.267

5.  A Structure-Function-Inhibition Analysis of the Pseudomonas aeruginosa Type III Secretion Needle Protein PscF.

Authors:  Donald T Moir; Nicholas O Bowlin; Bryan J Berube; Jaden Yabut; Debra M Mills; Giang T Nguyen; Zachary D Aron; John D Williams; Joan Mecsas; Alan R Hauser; Terry L Bowlin
Journal:  J Bacteriol       Date:  2020-08-25       Impact factor: 3.490

6.  Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Authors:  M J Dinubile; I Friedland; C Y Chan; M R Motyl; H Giezek; M Shivaprakash; R A Weinstein; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

7.  A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Authors:  Paul Warrener; Reena Varkey; Jessica C Bonnell; Antonio DiGiandomenico; Maria Camara; Kimberly Cook; Li Peng; Jingying Zha; Partha Chowdury; Bret Sellman; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

Review 8.  Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".

Authors:  Alberto Sandiumenge; Emili Diaz; Maria Bodí; Jordi Rello
Journal:  Intensive Care Med       Date:  2003-04-02       Impact factor: 17.440

9.  Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

Authors:  Mark J DiNubile; Joseph W Chow; Vilas Satishchandran; Adam Polis; Mary R Motyl; Murray A Abramson; Hedy Teppler
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

10.  Variation of infected cell count in bronchoalveolar lavage and timing of ventilator-associated pneumonia.

Authors:  Hervé Dupont; Viviane Chalhoub; Gaëtan Plantefève; Cyrille De Vaumas; Nathalie Kermarrec; Catherine Paugam-Burtz; Jean Mantz
Journal:  Intensive Care Med       Date:  2004-05-13       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.